Companies
FDA grants Etcamah accelerated approval for ESR1-mutated breast cancer
AZN's Etcamah enables a treatment switch when an ESR1 mutation emerges during aromatase inhibitor plus CDK4/6 inhibitor therapy. Median progression-free survival was 16 months versus 9.2 months in SERENA-6; overall survival remained imma...